伴侣蛋白通过辅助去乙酰化酶3调控脂肪酸氧化对抗饮食诱导的非酒精性脂肪性肝病
研究探讨线粒体伴侣蛋白热休克蛋白60(HSP60)在饮食诱导的非酒精性脂肪性肝病(NAFLD)中的作用。在人类NAFLD活检、高脂饮食诱导肥胖小鼠、Hsp60过表达转基因小鼠及HepG2细胞中,HSP60表达降低与严重脂肪变性相关,过表达HSP60可减少体脂、改善胰岛素抵抗和肝脏脂肪变性,并通过维持SIRT3信号促进脂肪酸氧化、抑制线粒体应激和炎症。
要点
- 人类NAFLD活检和小鼠饮食诱导肥胖中HSP60表达降低与严重脂肪变性相关。
- Hsp60过表达转基因小鼠在高脂饮食下体脂更少、血清甘油三酯更低、胰岛素抵抗更轻、血清脂联素更高。
- HSP60通过维持SIRT3信号促进脂肪酸氧化并抑制线粒体应激和炎症,改善NAFLD。
核心结论
- 线粒体HSP60通过维持SIRT3信号促进脂肪酸氧化并抑制线粒体应激和炎症,从而改善NAFLD的发生发展。
- 本研究揭示HSP60的肝脏保护作用,提示HSP60可能在NAFLD或2型糖尿病治疗开发中发挥基础性作用。
研究设计与样本
- 研究纳入人类NAFLD活检标本、高脂饮食(60%能量来自脂肪)诱导肥胖小鼠、过表达Hsp60的转基因(Tg)小鼠以及转染HSP60 cDNA或HSP60 siRNA的人HepG2细胞。
- 采用组织形态计量学评估肝脏脂肪变性,生化试剂盒测量胰岛素抵抗和葡萄糖耐量,自动家庭笼表型分析系统评估能量消耗,MRI评估体脂。
- 采用免疫组化检测巨噬细胞浸润、脂质氧化标志物4-羟基-2-壬烯醛(4-HNE)和氧化损伤标志物8-羟基-2'-脱氧鸟苷(8-OHdG),尼罗红染色评估细胞内脂滴。
- 采用RT-PCR和免疫印迹定量HSP60表达及脂肪生成和脂肪酸氧化标志物,数据分析使用双因素方差分析。
主要发现
- 人类NAFLD活检和小鼠饮食诱导肥胖中HSP60表达降低与严重脂肪变性相关。
- 高脂饮食喂养下,Hsp60转基因小鼠较野生型小鼠体脂更少、血清甘油三酯水平更低、胰岛素抵抗水平更低、血清脂联素水平更高。
- 呼吸商谱提示Hsp60转基因小鼠的脂肪可能被代谢以满足能量需求。
- Hsp60转基因小鼠显示高脂饮食介导的肝脏脂肪变性、M1/M2巨噬细胞失调以及4-HNE和8-OHdG过度产生得到改善。
- 强制HSP60表达降低线粒体未折叠蛋白反应,同时保持线粒体呼吸复合物活性并增强脂肪酸氧化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The mitochondrial chaperonin heat shock protein (HSP) 60 is indispensable in protein folding and the mitochondrial stress response; however, its role in nutrient metabolism remains uncertain. This study investigated the role of HSP60 in diet-induced non-alcoholic fatty liver disease (NAFLD). METHODS: We studied human biopsies from individuals with NAFLD, murine high-fat-diet (HFD; a diet with 60% energy from fat)-induced obesity (DIO), transgenic (Tg) mice overexpressing Hsp60 (Hsp60-Tg), and human HepG2 cells transfected with HSP60 cDNA or with HSP60 siRNA. Histomorphometry was used to assess hepatic steatosis, biochemistry kits were used to measure insulin resistance and glucose tolerance, and an automated home cage phenotyping system was used to assess energy expenditure. Body fat was assessed using MRI. Macrophage infiltration, the lipid oxidation marker 4-hydroxy-2-nonenal (4-HNE) and the oxidative damage marker 8-hydroxy-2'-deoxyguanosine (8-OHdG) were detected using immunohistochemistry. Intracellular lipid droplets were evaluated by Nile red staining. Expression of HSP60, and markers of lipogenesis and fatty acid oxidation were quantified using RT-PCR and immunoblotting. Investigations were analysed using the two-way ANOVA test. RESULTS: Decreased HSP60 expression correlated with severe steatosis in human NAFLD biopsies and murine DIO. Hsp60-Tg mice developed less body fat, had reduced serum triglyceride levels, lower levels of insulin resistance and higher serum adiponectin levels than wild-type mice upon HFD feeding. Respiratory quotient profile indicated that fat in Hsp60-Tg mice may be metabolised to meet energy demands. Hsp60-Tg mice showed amelioration of HFD-mediated hepatic steatosis, M1/M2 macrophage dysregulation, and 4-HNE and 8-OHdG overproduction. Forced HSP60 expression reduced the mitochondrial unfolded protein response, while preserving mitochondrial respiratory complex activity and enhancing fatty acid oxidation. Furthermore, HSP60 knockdown enhanced intracellular lipid formation and loss of sirtuin 3 (SIRT3) signalling in HepG2 cells upon incubation with palmitic acid (PA). Forced HSP60 expression improved SIRT3 signalling and repressed PA-mediated intracellular lipid formation. SIRT3 inhibition compromised HSP60-induced promotion of AMP-activated protein kinase (AMPK) phosphorylation and peroxisome proliferator-activated receptor α (PPARα levels), while also decreasing levels of fatty acid oxidation markers. CONCLUSION/INTERPRETATION: Mitochondrial HSP60 promotes fatty acid oxidation while repressing mitochondrial stress and inflammation to ameliorate the development of NAFLD by preserving SIRT3 signalling. This study reveals the hepatoprotective effects of HSP60 and indicates that HSP60 could play a fundamental role in the development of therapeutics for NAFLD or type 2 diabetes.
引用
- Weng SW, Wu JC, Shen FC, et al. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation. Diabetologia. 2023. PMID: 36692509. doi:10.1007/s00125-023-05869-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。